Loading patent…
AssigneeAgennix, Inc.
InventorsAtul Varadhachary, Federica Pericle
Estimating the term…
The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells by administering a composition of lactoferrin to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with lactoferrin to attenuate the development of graft-versus-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with lactoferrin to attenuate the development of graft rejection in the recipients.
A method of treating tissue or organ transplant rejection in a recipient comprising the step of administering to the recipient an effective amount of a lactoferrin composition to attenuate the tissue or organ transplant rejection.
The method of sentence 1 wherein said lactoferrin composition reduces allogeneic immune responses in the recipient.
The method of sentence 1, wherein the tissue is bone marrow or peripheral stem cells.
The method of sentence 1, wherein the organ is kidney, heart, lung, liver, or pancreas.
The method of sentence 1 wherein said lactoferrin composition regulates T cell responses by inducing transplant tolerance in the recipient.
The method of sentence 1, wherein said lactoferrin composition is dispersed in a pharmaceutically acceptable carrier.
The method of sentence 1, wherein said lactoferrin is mammalian lactoferrin.
The method of sentence 7, wherein said lactoferrin is human or bovine.
The method of sentence 1, wherein said lactoferrin is recombinant lactoferrin.
The method of sentence 1, wherein said lactoferrin composition is administered orally.
The method of sentence 1, wherein said lactoferrin composition is administered parenterally.
The method of sentence 13 further comprising administering an antacid in conjunction with said lactoferrin composition.
The method of sentence 13 further comprising administering the lactoferrin in a delayed release formulation.
The method of sentence 16, wherein the lactoferrin release occurs in the small intestine.
The method of sentence 16, wherein the lactoferrin release occurs in the large intestine.
The method of sentence 1, wherein the amount of the lactoferrin composition that is administered is about 1 mg to about 20 g per day.
The method of sentence 1, wherein the amount of the lactoferrin composition that is administered is about 0.1 g to about 5 g per day.
The method of sentence 1, wherein said lactoferrin modulates the mucosal or systemic immune system in a subject by increasing the amount of lactoferrin in the gastrointestinal tract.
The method of sentence 21, wherein said lactoferrin stimulates interleukin-18 or MIP-3-alpha in the gastrointestinal tract.
The method of sentence 21, wherein said lactoferrin regulates the activity of immune cells.
The method of sentence 21, wherein the immune cells are B and T lymphocytes, antigen-presenting cells, natural killer cells, macrophages and granulocytes.
The method of sentence 24, wherein the T lymphocytes are selected from the group consisting of CD4+/CD3+, CD8+/CD3+cells and NK-T cells.
The method of sentence 21, wherein said lactoferrin regulates the production or activity of pro-inflammatory cytokines.
The method of sentence 1 further comprising administering a metal chelator dispersed in a pharmaceutically acceptable carrier.
The method of sentence 27, wherein the metal chelator is ethylenediaminoetetracacetic acid (EDTA) or [etheylenebis(oxyethylenenitrilo)]tetraacetic acid (EGTA).
The method of sentence 28, wherein the metal chelator is EDTA.
The method of sentence 29, wherein the amount of EDTA that is administered is about 1 ng to about 1 g per day.
The method of sentence 1, further comprising administering an immunosuppressive agent, anti-rejection agent or anti-GVHD therapy in combination with the lactoferrin composition.
The method of sentence 31, wherein the immunosupressive agent is selected from the group consisting of cyclosporine, prednisone, azathioprine, tacrolimus and mycophenolate mofetil.
A method of preventing tissue or organ transplant rejection in a recipient comprising the step of administering to the recipient an effective amount of a lactoferrin composition to prevent the tissue or organ transplant rejection.
A method of modulating the immune response against an organ or tissue transplant in a recipient comprising the step of administering to the recipient an effective amount of a lactoferrin composition to modulate the response against the organ or tissue transplant.
A method of treating graft-versus-host-disease in a recipient comprising the step of administering to the recipient an effective amount of a lactoferrin composition to attenuate the graft-versus-host-disease in the recipient.
The method of sentence 35 further comprising treating ex vivo the donor organ or tissue with the lactoferrin composition.
The method of sentence 36, wherein the tissue is a stem cell.
The method of sentence 36, wherein the tissue is bone marrow or peripheral stem cells.
A method of treating graft-versus-host-disease comprising the step of administering an effective amount of a lactoferrin composition to the donor organ or donor tissue prior to transplantation into the recipient.
A method of preventing graft-versus-host-disease in a recipient comprising the step of administering to the recipient an effective amount of a lactoferrin composition to prevent the graft-versus-host-disease in the recipient.
The method of sentence 40 further comprising treating ex vivo the donor organ or tissue with the lactoferrin composition.
The method of sentence 41, wherein the tissue is a stem cell.
A method of treating tissue or organ transplant rejection in a recipient comprising the step of administering to the donor an effective amount of a lactoferrin composition to attenuate the tissue or organ transplant rejection in the recipient.
A method of treating xenograft tissue or xenograft organ transplant rejection in a recipient comprising the step of administering to the xenograft donor an effective amount of a lactoferrin composition to attenuate the tissue or organ transplant rejection in the recipient.
Dependencies are inferred from the claim text.